Alvotech
Biosimilar developer, Iceland. 5 development products across 5 molecules: adalimumab, aflibercept, denosumab, golimumab, ustekinumab.
First approval in the Atlas: Nov 2021, Libmyris, adalimumab (EMA)
FDAproducts approved2
EMAproducts approved5
PMDAproducts approved0
HCproducts approved2
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Adalimumab | Simlandi / Hukyndra / Libmyris AVT02 | Feb 2024 | Nov 2021 | · | Jan 2022 | · | · |
| Aflibercept | Afiveg / Mynzepli AVT06 | · | Aug 2025 | · | · | · | · |
| Denosumab | Zvogra / Kefdensis / Xbonzy / Acvybra AVT03 | · | Nov 2025 | · | · | · | · |
| Golimumab | Gobivaz / Gotenfia AVT05 | · | Nov 2025 | · | · | · | · |
| Ustekinumab | Selarsdi / Uzpruvo / Usgena AVT04 | Apr 2024 | Jan 2024 | · | Nov 2023 | · | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- EMANov 2021Libmyris, adalimumab
- EMANov 2021Hukyndra, adalimumab
- HCJan 2022Simlandi, adalimumab
- HCNov 2023Jamteki, ustekinumab
- EMAJan 2024Uzpruvo, ustekinumab
- FDAFeb 2024Simlandi, adalimumab
- FDAApr 2024Selarsdi, ustekinumab
- EMAAug 2025Afiveg, aflibercept
- EMAAug 2025Mynzepli, aflibercept
- EMANov 2025Acvybra, denosumab
- EMANov 2025Gobivaz, golimumab
- EMANov 2025Kefdensis, denosumab
- EMANov 2025Usgena, ustekinumab
- EMANov 2025Xbonzy, denosumab
- EMANov 2025Zvogra, denosumab
- EMAFeb 2026Gotenfia, golimumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.